CelLBxHealth ANPCF Stock
CelLBxHealth Price Chart
CelLBxHealth ANPCF Financial and Trading Overview
| CelLBxHealth stock price | 0.02 USD |
| Previous Close | 0.02 USD |
| Open | 0.01 USD |
| Bid | 0.02 USD x 3000000 |
| Ask | 0.02 USD x 1000000 |
| Day's Range | 0.01 - 0.01 USD |
| 52 Week Range | 0.01 - 0.11 USD |
| Volume | 20K USD |
| Avg. Volume | 4 USD |
| Market Cap | 22.61M USD |
| Beta (5Y Monthly) | 0.413 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.05 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
ANPCF Valuation Measures
| Enterprise Value | 21.06M USD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 19.630568 |
| Price/Book (mrq) | 3.6906526 |
| Enterprise Value/Revenue | 18.279 |
| Enterprise Value/EBITDA | -3.449 |
Trading Information
CelLBxHealth Stock Price History
| Beta (5Y Monthly) | 0.413 |
| 52-Week Change | -81.23% |
| S&P500 52-Week Change | 18.32% |
| 52 Week High | 0.11 USD |
| 52 Week Low | 0.01 USD |
| 50-Day Moving Average | 0.02 USD |
| 200-Day Moving Average | 0.02 USD |
ANPCF Share Statistics
| Avg. Volume (3 month) | 4 USD |
| Avg. Daily Volume (10-Days) | 0 USD |
| Shares Outstanding | 1.14B |
| Float | 491.63M |
| Short Ratio | N/A |
| % Held by Insiders | 5.69% |
| % Held by Institutions | 33.29% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -444.054% |
| Gross Margin | -28.90% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -37.23% |
| Return on Equity (ttm) | -163.78% |
Income Statement
| Revenue (ttm) | 1.15M USD |
| Revenue Per Share (ttm) | 0.002 USD |
| Quarterly Revenue Growth (yoy) | -25.00000000000000000000000000000000% |
| Gross Profit (ttm) | -333000 USD |
| EBITDA | -6105000 USD |
| Net Income Avi to Common (ttm) | -12942000 USD |
| Diluted EPS (ttm) | -0.05 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 2.88M USD |
| Total Cash Per Share (mrq) | 0.003 USD |
| Total Debt (mrq) | 1.31M USD |
| Total Debt/Equity (mrq) | 31.9 USD |
| Current Ratio (mrq) | 2.54 |
| Book Value Per Share (mrq) | 0.005392 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -8663000 USD |
| Levered Free Cash Flow (ttm) | -2036500 USD |
Profile of CelLBxHealth
| Country | United States |
| State | N/A |
| City | Guildford |
| Address | Surrey Research Park |
| ZIP | GU2 7AF |
| Phone | 44 14 8334 3434 |
| Website | https://cellbxhealth.com |
| Industry | Diagnostics & Research |
| Sector(s) | Healthcare |
| Full Time Employees | 114 |
CelLBxHealth plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated downstream analysis; and Parsortix PR1 system captures and harvests circulating tumour cells from blood. It also provides Portrait+ CTC Staining kit, a ready-to-use laboratory kit with analytical sensitivity and specificity for the identification, characterization, and enumeration of epithelial and mesenchymal circulating tumour cells; and CellKeep Slide, a CTC harvesting technology. In addition, the company offers laboratory services, including CTC enrichment and liquid biopsy analysis services; Portrait Flex, an immunofluorescence assay for the identification of epithelial, mesenchymal, and epithelial-to-mesenchymal transition; DNA damage response; Portrait PD-L1, evaluates CTCs; and custom CTC assays. CelLBxHealth plc has a strategic partnership with BioView Ltd to develop a human epidermal growth factor receptor 2 assay kit for breast cancer; and agreement with NuProbe USA, Inc. to use pan-cancer next generation sequencing (NGS) panel. The company also has a research collaboration with The Royal Marsden NHS Foundation Trust. The company was formerly known as ANGLE plc and changed its name to CelLBxHealth plc in October 2025. CelLBxHealth plc was founded in 1994 and is based in Guildford, the United Kingdom.
Q&A For CelLBxHealth Stock
What is a current ANPCF stock price?
CelLBxHealth ANPCF stock price today per share is 0.02 USD.
How to purchase CelLBxHealth stock?
You can buy ANPCF shares on the OTC Markets OTCQB exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for CelLBxHealth?
The stock symbol or ticker of CelLBxHealth is ANPCF.
Which industry does the CelLBxHealth company belong to?
The CelLBxHealth industry is Diagnostics & Research.
How many shares does CelLBxHealth have in circulation?
The max supply of CelLBxHealth shares is 1.14B.
What is CelLBxHealth Price to Earnings Ratio (PE Ratio)?
CelLBxHealth PE Ratio is now.
What was CelLBxHealth earnings per share over the trailing 12 months (TTM)?
CelLBxHealth EPS is -0.05 USD over the trailing 12 months.
Which sector does the CelLBxHealth company belong to?
The CelLBxHealth sector is Healthcare.
